Embark Early Education Ltd
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Recursion gains FDA clearance for Phase 1/2 cancer drug trial
Recursion, a TechBio company, received FDA clearance for a Phase 1/2 trial of REC-1245, targeting solid tumors and lymphoma, set to start in Q4 2024. The drug, developed using AI, targets RBM39, potentially addressing a significant unmet need. Recursion's platform combines experimental and computational approaches for drug discovery.
Evotec enters technology development partnership with Novo Nordisk in cell therapy
Evotec SE partners with Novo Nordisk for cell therapy technology development, focusing on stem cell-based off-the-shelf products. Novo Nordisk funds R&D at Evotec's sites in Germany and Italy, with an option for exclusive rights in a therapeutic area. Both companies aim to advance stem cell-based therapies for various diseases.
U.S. Drug Discovery Outsourcing Market Size to Reach USD 3.44 Billion By 2033
The U.S. drug discovery outsourcing market was valued at USD 1.85 billion in 2023, expected to reach USD 3.44 billion by 2033, driven by public-private partnerships, disease prevalence, and AI advancements. Key segments include lead identification & candidate optimization, respiratory system, and small molecules.
Pfizer withdraws sickle cell drug Oxbryta from worldwide markets
Pfizer withdraws sickle cell drug Oxbryta from worldwide markets; Evotec partners with Novo Nordisk on stem cell therapy manufacturing.
Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors
Aptadir Therapeutics launches with RNA inhibitors for intractable cancers and genetic conditions, developed by top institutions. Giovanni Amabile appointed as Executive Chairman and acting CEO. Received $1.6m pre-seed funding from EXTEND, a biopharmaceutical technology transfer hub.
IMU Biosciences expands leadership team with appointment of industry experts Dr. John
IMU Biosciences appoints Dr. John Baker as CEO and Dr. Jason Brown as CBO to expand leadership team, supporting growth in precision medicine.
First NCFB patient dosed in RESP-X Phase IIa study
Infex Therapeutics dosed the first NCFB patient in a Phase IIa study of RESP-X, a potential first-in-class anti-virulence antibody to treat chronic Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients, aiming to reduce exacerbations. The trial is a 12-patient, double-blind, placebo-controlled study at the NIHR Clinical Research Facility in Liverpool.
New Data Show Success of Type 1 Diabetes Treatment
Sernova Corp. presented positive interim data from its Phase I/II trials for its Cell Pouch™ Transplant System in treating Type 1 diabetes, showing long-term survival and function of islet cells. The system aims to provide a 'functional cure' by delivering therapeutic cells as a pseudo-organ. The data, presented by Dr. Piotr Witkowski, indicated robust vascularization and no detrimental tissue in the pouch after over five years. Sernova's CEO, Jonathan Rigby, highlighted the potential impact on quality of life for Type 1 diabetics. The company's technology also targets other chronic diseases and has potential for broader cell and protein delivery.
Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges
Evotec and Charles River Laboratories face restructuring due to reduced early-stage R&D spending, influenced by the Inflation Reduction Act's Medicare drug price negotiations and broader economic factors like rising interest rates. These pressures may shift biotech and pharma investment towards lower-risk projects, impacting areas like small molecules and precision medicine. Emerging biotech firms are particularly vulnerable, leading to increased M&A activity and strategic geographic relocations.
© Copyright 2025. All Rights Reserved by MedPath